MaxCyte Inc. reported a 15% year-over-year revenue decline for the second quarter of 2026 during an earnings call on Wednesday [1, 2].
The results highlight the company's struggle to maintain top-line growth while executing a strategic pivot to an enterprise model. This shift relies heavily on large-scale partnerships to stabilize income as traditional core revenue dips.
Total revenue for the quarter ended June 30 reached $7.3 million [2]. This figure represents a 15% decrease compared to the same period last year [2]. Within that total, core revenue fell to $6.5 million, marking a 21% year-over-year decline [2].
Other revenue streams provided a smaller portion of the quarterly total. Instrument revenue was $1.8 million, and license revenue also totaled $1.8 million [2].
Despite the drop in revenue, the company improved its bottom line. MaxCyte reported an adjusted loss per share of $0.08 [4]. This is a narrowing of the loss compared to the $0.12 per share loss reported in the second quarter of 2025 [4].
Management reiterated its full-year 2026 revenue outlook, projecting between $30 million and $32 million [3].
To support this guidance, the company highlighted an expanded partnership with Genentech. This collaboration is a central component of the company's move toward an enterprise model, a strategy designed to scale its technology through established industry leaders.
The company said on the call the revenue decline and how the narrowed loss reflects better cost management or operational efficiency during the transition [2, 3].
“MaxCyte reported a 15% year-over-year revenue decline for the second quarter of 2026.”
The divergence between falling core revenue and a narrowing net loss suggests MaxCyte is prioritizing operational leaness while it transitions its business model. By pivoting to an enterprise approach via the Genentech partnership, the company is attempting to reduce its reliance on fragmented sales and instead integrate its technology into larger, more stable corporate pipelines. The reiteration of the full-year guidance indicates management believes the second half of 2026 will offset the current quarterly decline.
